Following the US Supreme Court decision of Association for Molecular Pathology v Myriad Genetics Inc, 133 S Ct 2107 (2013) – in which the Court found patent claims to isolated naturally-occurring genomic DNA invalid – various parties have speculated about its effect on the development of new medical diagnostics and therapies. Some commentators have suggested that the rights excluded by the case are necessary for translation of scientific breakthroughs and will force some companies to rely on trade secrets, meanwhile others have submitted that the decision will have no practical significance. In this talk, I will present preliminary data from a novel patent claim-analysis technique designed to shed light on this speculation.
A light lunch will be provided. All are welcome.
For updates follow us on twitter: @OxIPDG